Gossamer Bio (GOSS) Gets a Buy From Oppenheimer
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Gossamer Bio Analyst Ratings
Promising Progress and Expansion Potential of Gossamer Bio's Seralutinib Drive Buy Rating
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Gossamer Bio Analyst Ratings
Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Gossamer Bio Analyst Ratings
Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9
Gossamer Bio Analyst Ratings
Goldman Sachs Maintains Buy on Gossamer Bio, Maintains $8 Price Target
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target